Vir Biotechnology
Biotechnology company focused on discovering and developing antibody-based medicines, T-cell engagers and related immunotherapies for infectious diseases, chronic hepatitis delta, oncology and other high unmet-need areas. The organization integrates antibody discovery and engineering, a proprietary AI-driven design platform, and a protease-releasable masking technology to advance candidates from discovery through clinical development and regulatory submissions. The company maintains academic and industry collaborations and runs registrational clinical programs.
Industries
Nr. of Employees
large (251-1000)
Patents
Products
elebsiran (siRNA)
Investigational siRNA designed for targeted delivery to the liver to reduce hepatitis B surface antigen and disrupt hepatitis delta virus lifecycle.
tobevibart (engineered monoclonal antibody)
Investigational neutralizing monoclonal antibody engineered for immune engagement used in combination with an siRNA in hepatitis delta programs.
PRO-XTEN-masked T-cell engagers (example: PSMA-targeted program)
Masked T-cell engager candidates using a protease-releasable mask intended to remain inactive in circulation and activate in the tumor microenvironment (example programs target PSMA, HER2, EGFR).
VIR-2981 (investigational influenza monoclonal antibody)
Monoclonal antibody candidate with potent in vitro activity against major influenza A and B strains, intended to reduce medically attended influenza illness in high-risk populations.
VIR-7229 (next-generation COVID-19 antibody)
Preclinical/early-clinical antibody optimized for potency, breadth and resistance to viral escape using AI-driven engineering.
VIR-1949 (T cell–based viral vector therapeutic vaccine)
Investigational therapeutic vaccine using a T-cell viral vector platform to elicit durable T-cell responses against HPV to treat high-grade precancerous lesions and clear underlying infection.
elebsiran (siRNA)
Investigational siRNA designed for targeted delivery to the liver to reduce hepatitis B surface antigen and disrupt hepatitis delta virus lifecycle.
tobevibart (engineered monoclonal antibody)
Investigational neutralizing monoclonal antibody engineered for immune engagement used in combination with an siRNA in hepatitis delta programs.
PRO-XTEN-masked T-cell engagers (example: PSMA-targeted program)
Masked T-cell engager candidates using a protease-releasable mask intended to remain inactive in circulation and activate in the tumor microenvironment (example programs target PSMA, HER2, EGFR).
VIR-2981 (investigational influenza monoclonal antibody)
Monoclonal antibody candidate with potent in vitro activity against major influenza A and B strains, intended to reduce medically attended influenza illness in high-risk populations.
VIR-7229 (next-generation COVID-19 antibody)
Preclinical/early-clinical antibody optimized for potency, breadth and resistance to viral escape using AI-driven engineering.
VIR-1949 (T cell–based viral vector therapeutic vaccine)
Investigational therapeutic vaccine using a T-cell viral vector platform to elicit durable T-cell responses against HPV to treat high-grade precancerous lesions and clear underlying infection.
Services
Collaborative development and co-commercialization arrangements with industry partners to accelerate global development and commercialization of therapeutics.
Collaborative development and co-commercialization arrangements with industry partners to accelerate global development and commercialization of therapeutics.
Expertise Areas
- Antibody discovery and engineering
- T-cell engager development
- AI-driven biologics design
- Protease-releasable masking and targeted activation
Key Technologies
- Monoclonal antibody engineering
- T-cell engager (TCE) platforms
- AI/ML-driven antibody design (dAIsY)
- Protease-releasable masking
News & Updates
Phase 3 registrational program evaluating the combination of an siRNA and an engineered monoclonal antibody for chronic hepatitis delta.
New England Journal of Medicine manuscript reporting that the combination produced undetectable hepatitis delta virus RNA (TND) in a majority of participants and showed favorable tolerability.
The investigational combination has received U.S. FDA Breakthrough Therapy and Fast Track designations, EMA PRIME designation, and orphan drug designation from the European Commission.
Phase 3 registrational program evaluating the combination of an siRNA and an engineered monoclonal antibody for chronic hepatitis delta.
New England Journal of Medicine manuscript reporting that the combination produced undetectable hepatitis delta virus RNA (TND) in a majority of participants and showed favorable tolerability.
The investigational combination has received U.S. FDA Breakthrough Therapy and Fast Track designations, EMA PRIME designation, and orphan drug designation from the European Commission.